Market research
27F.F Kala Pharmaceuticals, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 307K
- P/E ratio
- Not available
- Analyst target
- 14.79
- Dividend yield
- 0.0%
- Beta
- 1.15
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- US4831192020
- Market cap
- 307K
- P/E ratio
- Not available
- Analyst target
- 14.79
- Dividend yield
- 0.0%
- Beta
- 1.15
About
About Kala Pharmaceuticals, Inc
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 27F.F discussion.
5 years, 5 months ago
Kala Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 35.0% below its 200 day moving average.
From a valuation standpoint, the stock is 95.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 57.2.
Kala Pharmaceuticals, Inc's total revenue rose by 89.7% to $2M since the same quarter in the previous year.
Its net income has dropped by 41.7% to $-31M since the same quarter in the previous year.
Finally, its free cash flow fell by 43.5% to $-26M since the same quarter in the previous year.
Based on the above factors, Kala Pharmaceuticals, Inc gets an overall score of 2/5.